IP Library › Granted Patent US 7,071,205

Granted Patent B2

US 7,071,205 · App. 10/684,229 · Granted Jul 4, 2006

5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 7,071,205
App. No.: 10/684,229
Granted: Jul 4, 2006
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by Progesterone Receptor. Also provided are methods of making such compounds and pharmaceutical compositions.

Claims (286)

1. A compound of the formula:

wherein:

R 1 is selected from the group of hydrogen, C 1 –C 4 alkyl, C 1 –C 4 haloalkyl, C 1 –C 4 heteroalkyl, COR 11 , CO 2 R 11 , SO 2 R 11 , and CONR 11 R 12 ;

R 2 and R 3 each independently is selected from the group of hydrogen, C 1 –C 6 alkyl, and C 1 –C 6 haloalkyl; or

R 2 and R 3 taken together form a cycloalkyl ring of from three to twelve carbons;

R 4 through R 7 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR 11 , C 1 –C 4 alkyl, C 1 –C 4 haloalkyl, and C 1 –C 4 heteroalkyl; or

R 5 and R 7 taken together form a bond; or

R 6 and R 7 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;

R 8 through R 10 each independently is selected from the group of hydrogen, F, Cl, Br, I, NO 2 , CN, OR 11 , NR 11 R 12 , SR 11 , COR 11 , CO 2 R 11 , CONR 11 R 12 , C 1 –C 8 alkyl, C 1 –C 8 heteroalkyl, C 1 –C 8 haloalkyl, allyl, C 2 –C 8 alkenyl and C 2 –C 8 alkynyl;

R 11 and R 12 each is independently selected from the group of hydrogen, C 1 –C 4 alkyl, C 1 –C 4 heteroalkyl, and C 1 –C 4 haloalkyl;

R 13 is hydrogen;

R 14 through R 20 each independently is selected from the group of hydrogen, F, Cl, Br, OR 11 , C 1 –C 4 alkyl, C 1 –C 4 haloalkyl, and C 1 –C 4 heteroalkyl; or

R 14 and R 15 taken together are selected from the group of methylidene, carbonyl and thiocarbonyl; or

R 16 and R 17 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene, carbonyl and thiocarbonyl; or

R 14 and R 16 taken together form a bond or “—O—” bridge; or

R 16 and R 18 taken together form a bond when n is 1; or

R 16 and R 19 taken together form a bond when n is 0;

R 21 is hydrogen; or

R 21 and R 20 taken together form a bond;

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt thereof.

2. A compound of the formula:

wherein:

R 1 is selected from the group of hydrogen, C 1 –C 4 alkyl, C 1 –C 4 haloalkyl, C 1 –C 4 heteroalkyl, COR 11 , CO 2 R 11 , SO 2 R 11 , and CONR 11 R 12 ;

R 2 and R 3 each independently is selected from the group of hydrogen, C 1 –C 6 alkyl, and C 1 –C 6 haloalkyl; or

R 2 and R 3 taken together form a cycloalkyl ring of from three to twelve carbons;

R 4 through R 7 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR 11 , C 1 –C 4 alkyl, C 1 –C 4 haloalkyl, and C 1 –C 4 heteroalkyl; or

R 5 and R 7 taken together form a bond; or

R 6 and R 7 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;

R 11 and R 12 each is independently selected from the group of hydrogen, C 1 –C 4 alkyl, C 1 –C 4 heteroalkyl, and C 1 –C 4 haloalkyl;

R 13 is hydrogen; or

R 13 and R 14 taken together form a bond;

R 14 through R 20 each independently is selected from the group of hydrogen, F, Cl, Br, OR 11 , C 1 –C 4 alkyl, C 1 –C 4 haloalkyl, and C 1 –C 4 heteroalkyl; or

R 14 and R 15 taken together are selected from the group of methylidene, carbonyl and thiocarbonyl; or

R 16 and R 17 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene, carbonyl and thiocarbonyl; or

R 14 and R 16 taken together form a bond or “—O—” bridge;

R 16 and R 19 taken together form a bond when n is 0;

R 21 is hydrogen; or

R 21 and R 20 taken together form a bond;

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt thereof.

3. A compound of the formula:

wherein:

R 1 is selected from the group of hydrogen, C 1 –C 4 alkyl, C 1 –C 4 haloalkyl, C 1 –C 4 heteroalkyl, COR 11 , CO 2 R 11 , SO 2 R 11 , and CONR 11 R 12 ;

R 2 and R 3 each independently is selected from the group of hydrogen, C 1 –C 6 alkyl, and C 1 –C 6 haloalkyl; or

R 2 and R 3 taken together form a cycloalkyl ring of from three to twelve carbons;

R 4 through R 7 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR 11 , C 1 –C 4 alkyl, C 1 –C 4 haloalkyl, and C 1 –C 4 heteroalkyl; or

R 5 and R 7 taken together form a bond; or

R 6 and R 7 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;

R 11 and R 12 each is independently selected from the group of hydrogen, C 1 –C 4 alkyl, C 1 –C 4 heteroalkyl, and C 1 –C 4 haloalkyl;

R 13 is hydrogen; or

R 13 and R 14 taken together form a bond;

R 14 through R 20 each independently is selected from the group of hydrogen, F, Cl, Br, OR 11 , C 1 –C 4 alkyl, C 1 –C 4 haloalkyl, and C 1 –C 4 heteroalkyl; or

R 14 and R 15 taken together are selected from the group of methylidene, carbonyl and thiocarbonyl; or

R 16 and R 17 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene, carbonyl and thiocarbonyl; or

R 14 and R 16 taken together form a bond or “—O—” bridge; or

R 16 and R 18 taken together form a bond when n is 1; or

R 16 and R 19 taken together form a bond when n is 0;

R 21 is hydrogen;

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound of any one of claims 1 – 3 .

5. A compound according to any one of claims 1 , 2 or 3 , wherein R 1 is selected from the group of hydrogen, C 1 –C 4 alkyl, COR 11 , SO 2 R 11 , and CONR 11 R 12 .

6. A compound according to any one of claims 1 , 2 or 3 , wherein R 2 and R 3 each independently is selected from the group of C 1 –C 4 alkyl, and C 1 –C 4 haloalkyl.

7. A compound according to any one of claims 1 , 2 or 3 , wherein:

R 5 and R 7 taken together form a bond;

R 4 and R 6 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR 11 , C 1 –C 4 alkyl, and C 1 –C 4 haloalkyl.

8. A compound according to any one of claims 1 , 2 or 3 , wherein:

R 6 and R 7 taken together are selected from the group of methylidene, and carbonyl;

R 4 and R 5 each independently is selected from the group of hydrogen, F, and C 1 –C 4 alkyl.

9. A compound according to any one of claims 1 , 2 or 3 , wherein R 8 through R 10 each independently is selected from the group of hydrogen, F, Cl, Br, NO 2 , CN, OR 11 , SR 11 , C 1 –C 6 alkyl, C 1 –C 6 heteroalkyl, and C 1 –C 6 haloalkyl.

10. A compound according to claim 9 , wherein R 8 through R 10 each independently is selected from the group of hydrogen, F, and OR 11 .

11. A compound according to any one of claims 1 , 2 or 3 , wherein R 11 through R 12 each independently is selected from the group of hydrogen, and C 1 –C 4 alkyl.

12. A compound of the formula:

wherein:

R 1 is selected from the group of hydrogen, C 1 –C 4 alkyl, C 1 –C 4 haloalkyl, C 1 –C 4 heteroalkyl, COR 11 , CO 2 R 11 , SO 2 R 11 , and CONR 11 R 12 ;

R 2 and R 3 each independently is selected from the group of hydrogen, C 1 –C 6 alkyl, and C 1 –C 6 haloalkyl; or

R 2 and R 3 taken together form a cycloalkyl ring of from three to twelve carbons;

R 4 through R 7 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR 11 , C 1 –C 4 alkyl, C 1 –C 4 haloalkyl, and C 1 –C 4 heteroalkyl; or

R 5 and R 7 taken together form a bond; or

R 6 and R 7 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;

R 11 and R 12 each is independently selected from the group of hydrogen, C 1 –C 4 alkyl, C 1 –C 4 heteroalkyl, and C 1 –C 4 haloalkyl;

R 13 is hydrogen;

R 14 and R 16 taken together form a bond or “—O—” bridge;

R 15 , R 17 , R 18 , R 19 , R 20 each independently is selected from the group of hydrogen, F, Cl, C 1 –C 4 alkyl, and C 1 –C 4 haloalkyl.

R 21 is hydrogen; and

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt thereof.

13. A compound of the formula:

wherein:

R 1 is selected from the group of hydrogen, C 1 –C 4 alkyl, C 1 –C 4 haloalkyl, C 1 –C 4 heteroalkyl, COR 11 , CO 2 R 11 , SO 2 R 11 , and CONR 11 R 12 ;

R 2 and R 3 each independently is selected from the group of hydrogen, C 1 –C 6 alkyl, and C 1 –C 6 haloalkyl; or

R 2 and R 3 taken together form a cycloalkyl ring of from three to twelve carbons;

R 4 through R 7 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR 11 , C 1 –C 4 alkyl, C 1 –C 4 haloalkyl, and C 1 –C 4 heteroalkyl; or

R 5 and R 7 taken together form a bond; or

R 6 and R 7 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;

R 11 and R 12 each is independently selected from the group of hydrogen, C 1 –C 4 alkyl, C 1 –C 4 heteroalkyl, and C 1 –C 4 haloalkyl;

R 13 is hydrogen;

R 14 , R 15 , R 18 , R 19 , R 20 each independently is selected from the group of hydrogen, F, Cl, C 1 –C 4 alkyl, and C 1 –C 4 haloalkyl.

R 16 and R 17 taken together are selected from the group of methylidene, mono-substituted methylidene, and di-substituted methylidene;

R 21 is hydrogen; or

R 21 and R 20 taken together form a bond;

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt thereof.

14. A compound of the formula:

wherein:

R 1 is selected from the group of hydrogen, C 1 –C 4 alkyl, C 1 –C 4 haloalkyl, C 1 –C 4 heteroalkyl, COR 11 , CO 2 R 11 , SO 2 R 11 , and CONR 11 R 12 ;

R 2 and R 3 each independently is selected from the group of hydrogen, C 1 –C 6 alkyl, and C 1 –C 6 haloalkyl; or

R 2 and R 3 taken together form a cycloalkyl ring of from three to twelve carbons;

R 4 through R 7 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR 11 , C 1 –C 4 alkyl, C 1 –C 4 haloalkyl, and C 1 –C 4 heteroalkyl; or

R 5 and R 7 taken together form a bond; or

R 6 and R 7 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;

R 11 and R 12 each is independently selected from the group of hydrogen, C 1 –C 4 alkyl, C 1 –C 4 heteroalkyl, and C 1 –C 4 haloalkyl;

R 13 is hydrogen;

R 14 , R 15 , R 17 , R 20 each independently is selected from the group of hydrogen, F, Cl, C 1 –C 4 alkyl, and C 1 –C 4 haloalkyl R 16 and R 18 taken together form a bond when n is 1;

R 16 and R 19 taken together form a bond when n is 0;

R 21 is hydrogen; and

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt thereof.

15. A compound selected from the group of:

(±)-(5l, 1′l)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 24);

(±)-(5l, 1′u)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 25);

(+)-(5l,1′l)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 27);

(−)-(5l,1′l)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 28);

(±)-(5l,1′l)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 29);

(±)-(5l,1′u)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 30);

(+)-(5l,1′l)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 32);

(−)-(5l,1′l)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 33);

(±)-(5l,1′l)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 34);

(±)-(5l,1′u)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 35);

(+)-(5l,1′l)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 37);

(−)-(5l,1′l)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 38);

(±)-(5l,1′l)-5-(3-methyl-2-cyclohexenyl)-9-methoxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 39);

(±)-(5l,1′l)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2-dimethyl-5H-chromeno[3,4-f]quinoline (compound 41);

(±)-(5l,1′u)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2-dimethyl-5H-chromeno[3,4-f]quinoline (compound 42);

(±)-(5l,1′l)-5-(3-methyl-2-cyclopentenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 44);

(±)-(5l,1′u)-5-(3-methyl-2-cyclopentenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 45);

(±)-(5l,1′l)-5-(3,5,5-trimethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 47);

(±)-(5l,1′u)-5-(3,5,5-trimethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 48);

(±)-(5l,1′l)-5-(3-methyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 50);

(±)-(5l,1′u)-5-(3-methyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 51);

(±)-5-(3-methyl-3-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 52);

(±)-5-(2-cyclopenta-1,3-dienyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 53);

(±)-(5l1′)-5-(3-ethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 55);

(±)-(5l,1′u)-5-(3-ethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 56);

(±)-(5l,1′l)-5-(3-methyl-2-cyclohexenyl)-7-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 58);

(±)-(5l,1′u)-5-(3-methyl-2-cyclohexenyl)-7-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 59);

(±)-(5l,1′l)-5-(3-ethyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 61);

(±)-(5l,1′l)-5-(3-ethylidenecyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 62);

(±)-(5l,1′l)-5-(3-methyl-3-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 63);

(±)-(5l,1′l)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-8-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 64);

(±)-(5l,1′u)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-8-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 65);

(±)-(5l,1′l)-5-(2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 67);

(±)-(5l,1′u)-5-(2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 68);

(±)-5-(1-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 69);

(±)-(5l,1′l)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 71);

(+)-(5l,1′l)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 73);

(−)-(5l,1′l)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 74);

(±)-(5l,1′l)-5-(2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 75);

(±)-(5l,1′u)-5-(2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 76);

(±)-(5l,1′l)-5-(2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-4-methylidene-5H-chromeno[3,4-f]quinoline (compound 77);

(±)-(5l,1′l)-5-(2-methylidenecyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 79);

(±)-(5l,1′u)-5-(2-methylidenecyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 80);

(±)-(5l,1′l)-5-(2-oxocyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 81);

(±)-(5l,1′u)-5-(2-oxocyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 82);

(±)-(5l,1′l)-5-(3-methyl-2-cyclohexenyl)-9-methoxy-1,2-dihydro-1,2,2,4-tetramethyl-5H-chromeno[3,4-f]quinoline (compound 83);

(±)-5-(2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]-quinoline (compound 84);

(±)-(5l,1′l)-5-(2,3-dimethyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 85);

(±)-5-(3-methylidene-cyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 87);

(±)-(5l,1′u)-5-(3-ethylidenecyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 88);

(±)-(5l,1′l)-5-(2-cycloheptenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 89);

(±)-(5l,1′l)-5-(2-cyclooctenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 91);

(±)-(5l,1′u)-5-(2-cyclooctenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 92);

(±)-(5l,1′l)-5-(2,3-epoxy-3-methylcyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 94);

(±)-(5l,1′l)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-4-methylene-5H-chromeno[3,4-f]quinolin-3-ol (Compound 95);

(±)-(5l,1′l)-5-(2,3-epoxy-2,3-dimethylcyclopentyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 96);

(±)-(5l,1′u)-5-(2,3-epoxy-3-methylcyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 97); and

(±)-(5l,1′l)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-5H-chromeno[3,4-f]quinolin-4-one (Compound 98).

16. A compound selected from the group of:

(±)-(5l,1′l)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 24);